Regional differences in breast cancer biomarkers in american indian and alaska native women

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness. Methods: A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and c2 tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done. Results: Significant regional differences in some biomarker expression levels were seen. No increase was observed in "triple-negative" breast cancer or Her2 overexpression in these cases. Conclusions: Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity. Impact: There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number3
DOIs
StatePublished - 2014

Fingerprint

North American Indians
Tumor Biomarkers
Biomarkers
Breast Neoplasms
Progesterone Receptors
Population Groups
Estrogen Receptors
Triple Negative Breast Neoplasms
Cyclin D
Mortality
Epidermal Growth Factor Receptor
Neoplasms
Adenocarcinoma
Breast
Gene Expression
Alaska Natives
Incidence
Research
Therapeutics

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Medicine(all)

Cite this

@article{744b734d862044fd9d42f5b0a6fab1ca,
title = "Regional differences in breast cancer biomarkers in american indian and alaska native women",
abstract = "Background: Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness. Methods: A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and c2 tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done. Results: Significant regional differences in some biomarker expression levels were seen. No increase was observed in {"}triple-negative{"} breast cancer or Her2 overexpression in these cases. Conclusions: Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity. Impact: There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes.",
author = "Kaur, {Judith S} and Vierkant, {Robert A.} and Hobday, {Timothy James} and Visscher, {Daniel W}",
year = "2014",
doi = "10.1158/1055-9965.EPI-13-0738",
language = "English (US)",
volume = "23",
pages = "409--415",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Regional differences in breast cancer biomarkers in american indian and alaska native women

AU - Kaur, Judith S

AU - Vierkant, Robert A.

AU - Hobday, Timothy James

AU - Visscher, Daniel W

PY - 2014

Y1 - 2014

N2 - Background: Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness. Methods: A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and c2 tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done. Results: Significant regional differences in some biomarker expression levels were seen. No increase was observed in "triple-negative" breast cancer or Her2 overexpression in these cases. Conclusions: Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity. Impact: There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes.

AB - Background: Breast cancer is not a homogeneous disease, but several different and unique subtypes defined by gene expression analysis. Incidence and mortality rates vary by almost 3-fold between Alaska (highest) and the Southwestern tribes (lowest). We hypothesized that these differences may be due to, in part, varying levels of biologic tumor aggressiveness. Methods: A biorepository of the North Central Cancer Treatment Group with 95 cases of American Indian and Alaska Native (AIAN) women with adenocarcinoma of the breast surgically treated from 1990 to 2000 was tested for several biomarkers. Comparison distributions of biomarker values across state of residence using t tests for continuous (p53, MIB-1, cyclin D) and ordinally scaled markers [EGF receptor (EGFR), BCL-2, Her2] and c2 tests of significance for binary markers [estrogen receptor (ER), progesterone receptor (PR)] were done. Results: Significant regional differences in some biomarker expression levels were seen. No increase was observed in "triple-negative" breast cancer or Her2 overexpression in these cases. Conclusions: Despite a 3-fold difference in breast cancer mortality in Alaska Native versus Southwestern American Indians, standard biomarkers such as ER, PR, and Her2 neu expression did not explain the disparity. Impact: There is a need for research to understand the biologic basis of breast cancer disparities in AIAN women. Potential for a prospective trial will be explored with tribes.

UR - http://www.scopus.com/inward/record.url?scp=84896504618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896504618&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-13-0738

DO - 10.1158/1055-9965.EPI-13-0738

M3 - Article

VL - 23

SP - 409

EP - 415

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -